BIO-key Q2’25 Revenue Rose 49% Driven by Increases Across All Three Segments; Launches “BIO-key CyberDefense Initiative” to Support Growing Global Investment in Military and Defense Preparedness; Investor Call 10am ET Today

Rhea-AI Summary

BIO-key International (NASDAQ: BKYI), a provider of Identity and Access Management solutions, reported strong Q2 2025 financial results with revenue increasing 49% to $1.7M. The growth was driven by increases across all segments, with software license fees up 4% to $806K, services revenue rising to $322K, and hardware sales significantly increasing to $569K.

The company launched its BIO-key CyberDefense Initiative to target the growing global defense market, particularly in Europe where EU member states are expected to spend €350B on defense by 2026. Notable Q2 achievements include securing over $600K in follow-on orders from a Foreign Defense Ministry and establishing their first major IAM deployment with a national bank in Mozambique.

Despite the revenue growth, the company reported a net loss of ($1.17M), or ($0.20) per share, though improved from ($1.67M) in Q2'24. Gross margin was 73%, down from 77% year-over-year due to increased hardware sales.

Positive

• Revenue increased 49% year-over-year to $1.7M
• Secured $600K+ in follow-on orders from Foreign Defense Ministry
• Operating expenses reduced by 8.5% to $2.3M
• Net loss improved to ($1.17M) from ($1.67M) year-over-year
• Cash position strengthened to $2.3M from $0.4M at end of 2024
• Reduced note payable to $0.3M from original $2.3M

Negative

• Gross margin declined to 73% from 77% year-over-year
• Still operating at a loss with ($1.17M) net loss in Q2
• R&D expenses increased 7.6% to $636K

HOLMDEL, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and tokenless enhanced biometric authentication, announced results for its second quarter (Q2’25) and six months (6M’25) ended June 30, 2025. BIO-key is hosting an investor call today at 10:00am ET (details below).

Q2 Key Highlights

• Foreign Defense Ministry Awarded BIO-key over $600K in Follow-On orders for Secure Biometric Access to Critical Information.
• BIO-key and Runlevel Secured First Major IAM Deployment with a National Bank in Mozambique, Extending a Growing List of Banking Customers.
• BIO-key Partnered with Cloud Distribution Co. of Saudi Arabia to Expand IAM and Biometric Security Solutions Across the Middle East [and with Arrow ECS Iberia to Strengthen Market Access in Spain and Portugal].
• Completed Initial Phase Biometric-Based Deployment for a New International Defense Agency Customer.

BIO-key CEO, Mike DePasquale commented, “BIO-key’s Q2 revenue improved both sequentially and versus last year as we make steady progress advancing our direct and channel sales efforts which have been refocused solely on BIO-key branded solutions principally in Europe, Middle East and Africa (EMEA) as well as domestic markets.

BIO-key CyberDefense Initiative
“In addition to ongoing engagement in core North American enterprise markets, we are pursuing the substantial potential for IAM and biometric enabled solutions within the global defense market. Building on our growing base of highly respected military and defense customers across Europe, South America and the Middle East, we are forming the BIO-key CyberDefense Initiative. We are assembling a team of seasoned cybersecurity sales and support resources with specific military and intelligence expertise to engage with leading defense industry prime contractors to expand our market reach and potential. We expect this initiative to be supported by the recent and significant ramp in European defense spending commitments, including the clear shift toward cyber resilience as a security priority for European nations.

“This initiative positions us as a trusted provider of MFA, IAM and biometric enabled solutions to Ministries of Defense, Armed Forces, Intelligence and defense-integrated partners to support classified access environments aligned with European Union, NATO and other cyber frameworks. EU Member states are expected to spend €350B or more on defense in 2026, with Germany alone boosting its defense budget by over 30% to €83 billion from its 2025 level, with a meaningful portion set aside to ensure cyber resilience.

“We believe BIO-key’s successful track record in providing efficient, robust and highly secure authentication and identification solutions to the most discriminating defense sector IT groups puts us in a very strong position to capitalize on this opportunity both in Europe and around the globe. With a robust pipeline of existing opportunities, based on expected procurement cycles, we expect to see meaningful contract activity in the first half of next year.

“Turning back to our Q2’25 performance, gross margin moderated to 73% vs. 77% in Q2’24, reflecting an increase in hardware sales as a percentage of total revenue. We made further progress reducing total operating expenses to $2.3M in Q2’25 vs. $2.5M in Q2’24 as we trimmed selling, general and administrative expense by 13.5% compared to last year, more than offsetting a $45,000 increase in R&D expense. Q2’25 SG&A did reflect roughly $0.3M in expenses related to our global sales efforts, as well as the launch of new marketing initiatives that capitalize on customer traction and our core strengths in biometric enabled identification. Our R&D investments are currently advancing a significant platform modernization and deployment improvements for PortalGuard IDaaS. This is the first major upgrade of the platform since 2018, with a targeted release in Q4’25.

“With increasing interest in our biometric solutions, growing adoption of passwordless, phoneless and tokenless IAM solutions, a strong margin profile, and revenue traction in EMEA markets, we are optimistic about our growth outlook. We feel that the security, flexibility, ease of deployment and the compelling ROI of our solutions, combined with growing market acceptance of the need, should position us to deliver improved top- and bottom-line results in 2025. Of course the timing of large customer orders or renewals is likely to cause quarter-to-quarter fluctuations in our financial performance. We also continue to pursue opportunities to reduce costs and lower our breakeven level to support our path to positive cash flow and profitability, while balancing these efforts with our product development and marketing efforts.”

Financial Results
Q2’25 revenues increased 49% to $1,696,907 from $1,141,286 a year ago, reflecting higher revenues across the business. Software license fees increased 4% to $806,087 in Q2’25 from $774,225 a year ago, principally due to the ramp up of BIO-key product sales in Europe, Middle East and Africa (EMEA) territories following the termination of sales and support of AuthControl products in Europe. BIO-key EMEA has been experiencing and expects to see growing engagement for its product suite based on the products’ unique combination of security, flexibility, biometric capabilities, ease of use, quick installation and [superior/compelling] value and return on investment relative to other solutions.

Services revenues increased to $321,996 in Q2’25 from $283,569 in Q2’24, largely due to custom services revenue related to a large upgrade for one customer. Q2’25 hardware sales increased to $568,824 from $83,492 in Q2’24, principally due to the expanding deployment of biometric security solutions of a long-term customer, as well as the sale of some of fully reserved hardware inventory.

Q2’25 gross profit increased 40% to $1,232,727 from $879,014 in Q2’24, reflecting gross margins of 73% and 77%, respectively. The gross profit decline is due primarily to the significant year-over-year increase in hardware revenues which carry lower margins.

Reflecting ongoing efforts to reduce costs across the business, BIO-key’s total operating expenses decreased by 8.5% to $2,316,577 from $2,533,100 in Q2’24. The improvement reflects a 13.5% reduction in SG&A expenses to $1,680,550 in Q2’25 from $1,941,866 in Q2’24, on lower administration, sales personnel costs, and professional service fees. RD&E expenses increased 7.6% to $636,027 compared to $591,234 in Q2’25, primarily related to increased professional services and personnel costs, offset by lower rent costs.

Reflecting higher revenues and the benefit of lower operating costs, BIO-key’s Q2’25 net loss improved to ($1,167,396), or ($0.20) per share, compared to ($1,666,950), or ($1.00) per share, in Q2’24. Per share results are based on weighted average basic shares outstanding of 5,821,133 in Q2’25 and 1,663,042 in Q2’24.

Balance Sheet
As of June 30, 2025, BIO-key’s total current assets were $4.0M, including $2.3M of cash and cash equivalents, $1.1M of net accounts receivable and due from factor, and $0.3M of inventory. This compares to total current assets of $1.9M, including $0.4M of cash and cash equivalents, $0.8M of net accounts receivable and due from factor, and $0.4M of inventory at December 31, 2024.

BIO-key further reduced its note payable by $0.4M in Q2’25, leaving a $0.3M balance on the original $2.3M note.

Call Details

Date / Time:	Wednesday, August 13th at 10 a.m. ET
Call Dial In #:	1-877-418-5460 U.S. or 1-412-717-9594 Int’l
Live Webcast / Replay:	Webcast & Replay Link– Available for 3 months.
Audio Replay:	1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 8281392

About BIO-key International, Inc. (www.BIO-key.com)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.

BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to migrate Swivel Secure customers to BIO-key and Portal Guard offerings; our ability to execute definitive agreements with Fiber Food Systems and/or its customers to utilize our access management solutions; our ability to integrate our solutions into any of Fiber Food System’s offerings; fluctuations in foreign currency exchange rates; the duration and extent of continued hostilities in Ukraine and its impact on our European customers; the impact of tariffs and other trade barriers which may make it more costly for us to import inventory from China and Hong Kong and certain product components from South Korea; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence of the restatement of our financial statements, including any consequences of non-compliance with Securities and Exchange Commission and Nasdaq periodic reporting requirements; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; any disruption to our business that may occur on a longer-term basis should we be unable to continue to maintain effective internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.

Engage with BIO-key

Facebook – Corporate:	https://www.facebook.com/BIOkeyInternational/
LinkedIn – Corporate:	https://www.linkedin.com/company/bio-key-international
X – Corporate:	@BIOkeyIntl
X – Investors:	@BIO_keyIR
StockTwits:	BIO_keyIR

Investor Contacts 
William Jones, David Collins
Catalyst IR 
BKYI@catalyst-ir.com or 212-924-9800

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)
		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2025				2024				2025				2024
Revenues
Services		$	321,996			$	283,569			$	594,594			$	496,690
License fees			806,087				774,225				1,904,845				2,724,659
Hardware			568,824				83,492				804,627				101,140
Total revenues			1,696,907				1,141,286				3,304,066				3,322,489
Costs and other expenses
Cost of services			118,301				73,385				216,445				212,234
Cost of license fees			86,488				148,432				159,373				296,652
Cost of hardware			536,806				40,455				645,275				53,029
Cost of hardware - reserve			(277,415	)			-				(277,415	)			-
Total costs and other expenses			464,180				262,272				743,678				561,915
Gross profit			1,232,727				879,014				2,560,388				2,760,574
Operating expenses
Selling, general and administrative			1,680,550				1,941,866				3,053,074				3,724,839
Research, development and engineering			636,027				591,234				1,231,802				1,198,755
Total operating expenses			2,316,577				2,533,100				4,284,876				4,923,594
Operating loss			(1,083,850	)			(1,654,086	)			(1,724,488	)			(2,163,020	)
Other income (expense)
Interest income			2,092				46				2,095				51
Loan fee amortization			(60,000	)			(4,000	)			(120,000	)			(4,000	)
Change in fair value of convertible note
Interest expense			(25,638	)			(8,910	)			(61,548	)			(10,267	)
Total other income (expense), net			(83,546	)			(12,864	)			(179,453	)			(14,216	)
Loss before provision for income tax			(1,167,396	)			(1,666,950	)			(1,903,941	)			(2,177,236	)
Provision for (income tax) tax benefit			-				-				-				-
Net loss		$	(1,167,396	)		$	(1,666,950	)		$	(1,903,941	)		$	(2,177,236	)
Comprehensive loss:
Net loss		$	(1,167,396	)		$	(1,666,950	)		$	(1,903,941	)		$	(2,177,236	)
Other comprehensive income (loss) – foreign currency translation adjustment			58,805				24,220				65,608				(38,530	)
Comprehensive loss		$	(1,108,591	)		$	(1,642,730	)		$	(1,838,333	)		$	(2,215,766	)
Basic and diluted loss per common share		$	(0.20	)		$	(1.00	)		$	(0.36	)		$	(1.33	)
Weighted average common shares outstanding:
Basic and diluted			5,821,133				1,663,042				5,267,109				1,639,183

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS
		June 30,				December 31,
		2025				2024
		(Unaudited)
ASSETS
Cash and cash equivalents		$	2,275,344			$	437,604
Accounts receivable, net			983,534				718,229
Due from factor			154,769				74,170
Inventory			318,538				378,307
Prepaid expenses and other			303,045				278,648
Total current assets			4,035,230				1,886,958
Equipment and leasehold improvements, net			102,499				140,198
Capitalized contract costs, net			367,125				409,426
Deposits and other assets			7,976				7,976
Operating lease right-of-use assets			60,829				73,372
Investments			5,000,000				5,000,000
Intangible assets, net			942,892				1,097,630
Total non-current assets			6,481,321				6,728,602
TOTAL ASSETS		$	10,516,551			$	8,615,560
LIABILITIES
Accounts payable		$	889,026			$	818,187
Accrued liabilities			1,170,889				1,278,732
Note payable			447,153				1,525,977
Government loan – BBVA Bank, current portion			125,562				132,731
Deferred revenue, current			873,394				773,267
Operating lease liabilities, current portion			25,886				24,642
Total current liabilities			3,531,910				4,553,536
Deferred revenue, long term			96,729				196,237
Government loan – BBVA Bank – net of current portion			-				44,762
Operating lease liabilities, net of current portion			35,735				48,994
Total non-current liabilities			132,464				289,993
TOTAL LIABILITIES			3,664,374				4,843,529
Commitments and Contingencies
STOCKHOLDERS’ EQUITY
Common stock — authorized, 170,000,000 shares; issued and outstanding; 6,848,776 and 3,715,483 of $.0001 par value at June 30, 2025 and December 31, 2024, respectively			685				372
Additional paid-in capital			137,948,437				133,030,271
Accumulated other comprehensive income			114,898				49,290
Accumulated deficit			(131,211,843	)			(129,307,902	)
TOTAL STOCKHOLDERS’ EQUITY			6,852,177				3,772,031
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	10,516,551			$	8,615,560

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
		Six Months Ended June 30,
		2025				2024
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss		$	(1,903,941	)		$	(2,177,236	)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation			43,748				46,069
Amortization of intangible assets			154,738				155,900
Amortization of capitalized contract costs			91,766				80,074
Amortization of note payable			120,000				-
Interest payable on note			60,175				-
Operating leases right-of-use assets			12,543				27,564
Share and warrant-based compensation for employees and consultants			74,325				96,561
Share-based directors’ fees			20,004				9,003
Bad debts			15,000				-
Change in assets and liabilities:
Accounts receivable			(15,305	)			297,480
Allowance for doubtful receivables			(250,000	)			-
Due from factor			(80,599	)			71,156
Capitalized contract costs			(49,465	)			(198,885	)
Inventory			59,769				12,558
Prepaid expenses and other			(24,397	)			(24,615	)
Accounts payable			71,322				258,384
Accrued liabilities			(107,843	)			(141,167	)
Deferred revenue			619				414,878
Operating lease liabilities			(7,783	)			(51,257	)
Net cash used in operating activities			(1,715,324	)			(1,123,533	)
CASH FLOW FROM INVESTING ACTIVITIES:
Capital expenditures			(6,048	)			(1,869	)
Net cash used in investing activities			(6,048	)			(1,869	)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from note payable			-				2,000,000
Offering costs			(248,783	)			(13,470	)
Proceeds for exercise of warrants			3,813,057				1,400
Receipt of cash from employee stock purchase plan			876				1,939
Repayment of government loan			(71,645	)			(77,461	)
Net cash provided in financing activities			3,493,505				1,912,408
Effect of exchange rate changes			65,608				(38,055	)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS			1,837,741				748,951
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD			437,604				511,400
CASH AND CASH EQUIVALENTS, END OF PERIOD		$	2,275,345			$	1,260,351

FAQ

What was BIO-key's (BKYI) revenue growth in Q2 2025?

BIO-key reported a 49% revenue increase to $1.7M in Q2 2025, with growth across all three business segments: software license fees, services, and hardware sales.

What is BIO-key's CyberDefense Initiative and its market potential?

The BIO-key CyberDefense Initiative targets the global defense market, particularly in Europe where EU members are expected to spend €350B on defense by 2026. The initiative focuses on providing IAM and biometric solutions to defense agencies and contractors.

How did BIO-key's (BKYI) profitability change in Q2 2025?

BIO-key's net loss improved to ($1.17M) from ($1.67M) year-over-year, with operating expenses reduced by 8.5% to $2.3M. However, gross margin declined to 73% from 77%.

What major contracts did BIO-key secure in Q2 2025?

BIO-key secured over $600K in follow-on orders from a Foreign Defense Ministry and established their first major IAM deployment with a national bank in Mozambique.

What is BIO-key's current cash position as of Q2 2025?

As of June 30, 2025, BIO-key had $2.3M in cash and cash equivalents, up from $0.4M at the end of 2024, with total current assets of $4.0M.